no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
|
Eapen, Mary |
|
2017 |
4 |
7 |
p. e325-e333 nvt p. |
article |
2 |
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
|
Clark, Richard E |
|
2017 |
4 |
7 |
p. e310-e316 nvt p. |
article |
3 |
Do big numbers assure high-quality of data?
|
Crocetti, Emanuele |
|
2017 |
4 |
7 |
p. e309- 1 p. |
article |
4 |
How to define treatment failure for JAK inhibitors
|
Kvasnicka, Hans Michael |
|
2017 |
4 |
7 |
p. e305-e306 nvt p. |
article |
5 |
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
|
Harrison, Claire N |
|
2017 |
4 |
7 |
p. e317-e324 nvt p. |
article |
6 |
Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study
|
Rawstron, Andy C |
|
2017 |
4 |
7 |
p. e334-e340 nvt p. |
article |
7 |
The DESTINY of chronic myeloid leukeamia
|
Abruzzese, Elisabetta |
|
2017 |
4 |
7 |
p. e303-e304 nvt p. |
article |
8 |
The need for better legislation for generic drug manufacturers
|
The Lancet Haematology, |
|
2017 |
4 |
7 |
p. e302- 1 p. |
article |
9 |
Unrelated cord blood transplantation for non-malignant diseases: every HLA allele counts
|
Scaradavou, Andromachi |
|
2017 |
4 |
7 |
p. e307-e308 nvt p. |
article |